Bi-functional SuperKine ImmunoTherapies (“BiSKITs”)
One Molecule, Two Functions
Our Superkine platform allows the use of fusion to enhance the capabilities of our naked IL-2, IL-4 and IL-13 Superkines which were created through directed evolution. For example, with MDNA11, albumin enhances the half-life of the drug allowing for a longer period between dosing, while with MDNA55, the fused toxin gives the Superkine a tumor-targeted killing capability.
These fusions are just the beginning of what Medicenna can create with its Superkine platform. Medicenna’s Superkines can be fused with a large variety of proteins, antibodies and even other Superkines to incorporate two synergistic mechanisms of action into one molecule: a BiSKIT.
BiSKITs are the natural evolution of Medicenna’s platform and allow us to create therapies that address a wide range of diseases, including those with significant unmet need.
Medicenna is planning to announce a lead BiSKIT candidate in the second half of 2021.